"Neurofibromin 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A membrane protein homologous to the ERM (Ezrin-Radixin-Moesin) family of cytoskeleton-associated proteins which regulate physical properties of membranes. Alterations in neurofibromin 2 are the cause of NEUROFIBROMATOSIS 2.
| Descriptor ID |
D025581
|
| MeSH Number(s) |
D12.776.543.685 D12.776.624.776.612
|
| Concept/Terms |
Neurofibromin 2- Neurofibromin 2
- Moesin-Ezrin-Radixin-Like Protein
- Moesin Ezrin Radixin Like Protein
- Schwannomin Protein
- Protein, Schwannomin
- Neurofibromatosis Type 2 Protein
- NF2 Gene Product
- Gene Product, NF2
- Schwannomin
- Merlin
- Neurofibromatosis 2 Gene Product
|
Below are MeSH descriptors whose meaning is more general than "Neurofibromin 2".
Below are MeSH descriptors whose meaning is more specific than "Neurofibromin 2".
This graph shows the total number of publications written about "Neurofibromin 2" by people in this website by year, and whether "Neurofibromin 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neurofibromin 2" by people in Profiles.
-
NF2 loss-of-function and hypoxia drive radiation resistance in grade 2 meningiomas. J Natl Cancer Inst. 2025 Jun 01; 117(6):1175-1187.
-
Update on Cancer and Central Nervous System Tumor Surveillance in Pediatric NF2-, SMARCB1-, and LZTR1-Related Schwannomatosis. Clin Cancer Res. 2025 Apr 14; 31(8):1400-1406.
-
Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features. Neuro Oncol. 2023 03 14; 25(3):520-530.
-
MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. Ophthalmology. 2022 09; 129(9):974-985.
-
NHERF1/EBP50 and NF2 as diagnostic markers for choroid plexus tumors. Acta Neuropathol Commun. 2016 05 27; 4(1):55.
-
Moesin is a glioma progression marker that induces proliferation and Wnt/?-catenin pathway activation via interaction with CD44. Cancer Res. 2013 Feb 01; 73(3):1142-55.
-
Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways. Mol Cancer Ther. 2011 Nov; 10(11):2094-103.
-
Regulation of mixed lineage kinase 3 is required for Neurofibromatosis-2-mediated growth suppression in human cancer. Oncogene. 2011 Feb 17; 30(7):781-9.
-
VprBP targets Merlin to the Roc1-Cul4A-DDB1 E3 ligase complex for degradation. Oncogene. 2008 Jul 03; 27(29):4056-64.
-
Mouse models in tumor suppression. Oncogene. 1998 Dec 24; 17(25):3385-400.